Standard and experimental therapy in cutaneous T-cell lymphomas.
Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by the accumulation of clonal lymphocytes in the skin. Skin-directed therapies are the preferred first-line modalities. There are interesting new developments in topical therapy using retinoids and gene-therapy products such as adenovirus- interferon (IFN)-gamma. Systemic treatment uses biologicals such as fusion molecules, monoclonal antibodies and immune response modifiers (IFNs and retinoids), and well-tolerated antiproliferative drugs such as methotrexate. Evidence-based treatment recommendation exists but is hampered by the lack of large multicenter randomized trials.
Dummer
Reinhard
R
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. reinhard.dummer@usz.ch
Cozzio
Antonio
A
Meier
Sibylle
S
Beyeler
Mirjam
M
Laetsch
Barbara
B
Doebbeling
Udo
U
Urosevic
Mirjana
M
D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*